PALISADE BIO, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
PALISADE BIO, INC. (PALI) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $1.12 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-20.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-03-20
- PALISADE BIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $2.36, a 143.30% increase year-over-year.
- PALISADE BIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2022-03-31 was $0.97.
- PALISADE BIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2019-03-31 was $0.43.
- PALISADE BIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2016-03-31 was $0.77, a 79.74% decline year-over-year.
- PALISADE BIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $1.12, a 75.33% decline from fiscal 2024.
- PALISADE BIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $4.54, a 226.62% increase from fiscal 2023.
- PALISADE BIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $1.39, a 96.55% decline from fiscal 2022.
- PALISADE BIO, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $40.32, a 1209.09% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month as first filed | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|---|
| 2025-12-31 | $1.12 10-K · filed 2026-03-20 | ||||
| 2024-12-31 | $4.54 10-K · filed 2025-03-24 | ||||
| 2023-12-31 | $1.39 10-K · filed 2024-03-26 | ||||
| 2023-09-30 | $1.64 10-Q · filed 2023-11-09 | ||||
| 2023-06-30 | $1.80 10-Q · filed 2023-08-10 | ||||
| 2023-03-31 | $2.36 10-Q · filed 2023-05-11 | ||||
| 2022-12-31 | $40.32 10-K · filed 2023-03-22 | ||||
| 2022-09-30 | $0.81 10-Q · filed 2022-11-14 | ||||
| 2022-06-30 | $0.89 10-Q · filed 2022-08-15 | ||||
| 2022-03-31 | $0.97 10-Q · filed 2022-05-13 | ||||
| 2021-12-31 | $3.08 10-K · filed 2022-03-17 | ||||
| 2021-09-30 | $17.72 10-Q · filed 2021-11-12 | ||||
| 2021-06-30 | $17.72 10-Q · filed 2021-08-23 | ||||
| 2020-12-31 | $0.62 10-K · filed 2021-03-22 | ||||
| 2020-09-30 | $0.62 10-Q · filed 2020-11-10 | ||||
| 2020-06-30 | $0.62 10-Q · filed 2020-08-13 | ||||
| 2019-12-31 | $7.78 10-K · filed 2020-03-27 | ||||
| 2019-09-30 | $7.78 10-Q · filed 2019-11-14 | ||||
| 2019-06-30 | $8.53 10-Q · filed 2019-08-14 | ||||
| 2019-03-31 | $0.43 10-Q · filed 2019-05-14 | ||||
| 2018-12-31 | $1.13 10-K · filed 2019-03-22 | ||||
| 2018-09-30 | $1.13 10-Q · filed 2018-11-14 | ||||
| 2017-12-31 | $1.92 10-K · filed 2018-04-02 | ||||
| 2017-09-30 | $5.08 10-Q · filed 2017-11-08 | ||||
| 2017-06-30 | $2.99 10-Q · filed 2018-08-13 | $4.96 10-Q · filed 2017-08-08 | |||
| 2016-12-31 | $7.91 10-K · filed 2017-03-23 | ||||
| 2016-09-30 | $0.61 10-Q · filed 2016-11-08 | ||||
| 2016-06-30 | $0.77 10-Q · filed 2016-08-11 | ||||
| 2016-03-31 | $0.77 10-Q · filed 2016-05-09 | ||||
| 2015-12-31 | $3.09 10-K · filed 2016-03-14 | ||||
| 2015-09-30 | $3.09 10-Q · filed 2015-11-09 | ||||
| 2015-06-30 | $3.61 10-Q · filed 2015-08-10 | ||||
| 2015-03-31 | $3.80 10-Q · filed 2015-05-08 | ||||
| 2014-12-31 | $3.20 10-K · filed 2015-03-16 | ||||
| 2014-09-30 | $3.26 10-Q · filed 2014-11-07 | ||||
| 2014-06-30 | $3.43 10-Q · filed 2014-08-08 | ||||
| 2014-03-31 | $3.22 10-Q · filed 2014-05-12 | ||||
| 2013-12-31 | $1.11 10-K · filed 2014-03-10 | ||||
| 2013-09-30 | $1.12 10-Q · filed 2013-11-12 | ||||
| 2013-06-30 | $1.12 10-Q · filed 2013-08-08 | ||||
| 2013-03-31 | $1.12 10-Q · filed 2013-05-10 | ||||
| 2012-12-31 | $0.99 10-K · filed 2013-03-15 | ||||
| 2012-09-30 | $0.99 10-Q · filed 2012-11-09 | ||||
| 2012-06-30 | $1.09 10-Q · filed 2012-08-09 | ||||
| 2011-12-31 | $1.50 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |